Huvudbild för Pareto Securities’ 13th Annual Healthcare Conference
Profilbild för Bio-Works Technologies

Bio-Works Technologies Utställare

Presentation
Bio-Works designs, develops, manufactures and supplies innovative agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company has 9 product lines, which are used for purification in the life science research phases as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally both through direct sales and via distributors. Bio-Works’ headquarters, R&D and manufacturing facilities are located in Uppsala, Sweden.

Recent highlights
In Q1, the company’s product sales amounted to SEK 6.0M, an increase of 135% as compared to the same period one year ago. Sales increased fastest in North America to SEK 3.2M, with Asia also increased to SEK 0.8M. In March, Bio-Works signed a distributor agreement with Brennan & Co for the Irish and Northern Irish markets. In June, Bio-Works confirmed an order worth 2.3 MSEK by an American contract manufacturer with 17,000 employees globally. Lastly, Bio-Works launched a new product line, GoBio, in June. GoBio is a prepacked chromatography column designed to save time in biotherapeutic production, spanning the entire production cycle from process development to commercial production.

Outlook
Bio-Works’ focus for 2022 will be to strengthen its market position as a specialist at the leading edge of chromatographic separation, prioritise short lead times and reliable deliveries, and reduce operating losses and become profitable during the coming years.

Programpunkter

Bio-Works Technologies

Torsdag 8 september 2022 15:45 - 16:15 CEST Bankvalvet

Representanter

Jonathan Royce FöreläsareUtställare

CEO
Bio-Works Technologies

David Nelander Utställare

CFO
Bio-Works Technologies